
Edison Group’s new report Biosynthesis: Taking the cannabinoid market to new heights explores the growth potential for biosynthesis in the production of high-quality cannabinoids, following predictions that the global market for CPG and pharma cannabinoid biosynthesis products could reach $92 billion by 2040.
The report explores the potential of biotechnology to enable the growth of rare cannabinoids at a lower cost and faster pace than allowed by conventional methods such as fields, greenhouses or chemical synthesis. This will meet increasing demand driven by new legislation in geographies including the USA and Canada, as well as decreasing stigma associated with cannabis and growing consumer interest across sectors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze